To view this email as a web page, click here.
 
Review these psoriasis stories you may have missed, and test your knowledge on psoriatic arthritis by taking the quiz below.
 
Dermatology Times
JAK inhibitors offer multiple applications
Unlike prior generations of dermatologic drugs, JAK inhibitors show potential for treating numerous dermatologic indications.
ADVERTISEMENT
 
Ortho Dermatologics launches psoriasis topical
The novel halobetasol propionate and tazarotene, 0.01%.0.045%, lotion will be available to healthcare providers beginning this week.
 
Psoriatic Arthritis Quiz
image description here From Rheumatology Network
Test your knowledge on phenotypes unique to psoriatic arthritis by taking this quiz.

 
Biologics in the real world
image description here Why do biologics to lose efficacy after the initial response? This expert discusses factors that can reduce a drug's efficacy over time.

 
Connect with us on Twitter and Facebook for daily updates.
 
ADVERTISEMENT
Excess cellulite? Give your patients the power of choice
It’s bathing suit season. What treatment options do you have to offer? In this podcast, Michelle Foley, DO, reviews the VelaShape III's infrared light, bi-polar radiofrequency energy and vacuum technology, and Profound's nonsurgical micro-needling treatment. Listen to the podcast now.
 
From our Latest Issue
 
Dermatology Times cover
A patient-centered approach to psoriasis treatment
 
The complexities of nonphysician compensation
 
Melanoma therapies and the skin
 
JOB OPPORTUNITIES
 
CA - Integrated Dermatology
CO-Integrated Dermatology
CT - Integrated Dermatology
District of Columbia-Integrated Dermatology
MA - Integrated Dermatology
MA - Integrated Dermatology
MA - Integrated Dermatology
MD - Integrated Dermatology
MD - Integrated Dermatology
MS - Integrated Dermatology
National - Integrated Dermatology
NJ - Integrated Dermatology
NJ - Practice for Sale
NV - Integrated Dermatology
VA - Integrated Dermatology
VA - Integrated Dermatology
VT - Integrated Dermatology
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.